Caladrius Biosciences to Present at Upcoming November Conferences

Caladrius Biosciences to Present at Upcoming November Conferences

October 27, 2016

BASKING RIDGE, N.J., October 27, 2016 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that the Company’s leadership will present at the following upcoming November conferences:

Sidoti 2016 Emerging Growth Convention

ARM EU Advanced Therapies Investor Day

  • Date and Time:Thursday, November 3, 2016, 8:40 AM GMT
  • Website: http://eu.arminvestorday.com/
  • Venue:30 Euston Square, London, England
  • Topic:Fireside Chat: Immuno-oncology
  • Session Chair:Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations, Chief Technology Officer, and Director

Life Sciences Summit 2016

  • Date and Time:Thursday, November 3, 2016, 10:00 AM ET
  • Website: http://lifesciencessummit.org
  • Venue:Times Warner Center, New York, New York
  • Topic:Regenerative Medicine: Will iPS Cells Deliver as Promised?
  • Panelist:Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs, and Chief Medical Officer

American Heart Association Scientific Sessions

Session 1

  • Date and Time: Monday, November 14, 2016, 4:15 PM CT
  • Topic:Myocyte Preplacement for the Failing Heart
  • Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs, and Chief Medical Officer

Session 2

  • Date and Time: Tuesday, November 15, 2016, 4:30 PM CT
  • Topic:Endogenous Pro-Angiogenic Cells and MI
  • Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs, and Chief Medical Officer

2016 World Alliance Forum in San Francisco

  • Website: http://wafsf.org
  • Venue:The Golden Gate Club, San Francisco, California

Session 1

  • Date and Time: Monday, November 21, 2016, 9:15 AM PT
  • Topic:Overview: Cell & Gene Therapy
  • Presenter: Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations, Chief Technology Officer, and Director

Session 2

  • Date and Time: Tuesday, November 22, 2016, 9:10 AM PT
  • Topicl:Cell and Gene Therapy & Cancer Immunotherapy – Overview
  • Moderator: Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations, Chief Technology Officer, and Director

About Caladrius Biosciences

Caladrius Biosciences, Inc. is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset type 1 diabetes.  The product candidate, CLBS03, is the subject of an ongoing Phase 2 clinical trial (The Sanford Project: T-Rex study) in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration and Advanced Therapeutic Medicinal Product classification by the European Medicines Agency.  The Company’s PCT subsidiary is a leading development and manufacturing partner to the cell therapy industry.  PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise.   For more information, visit www.caladrius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.